Advertisement
U.S. Markets open in 9 hrs 10 mins
S&P Futures
5,885.25 -11.00 (-0.19%) Dow Futures
43,112.00 -65.00 (-0.15%) Nasdaq Futures
20,465.75 -53.75 (-0.26%) Russell 2000 Futures
2,248.80 -6.70 (-0.30%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,747.90 +9.00 (+0.33%)
VYNE Therapeutics Inc. (VYNE)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 2.2150 |
| Open | 2.1900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.1900 - 2.4200 |
| 52 Week Range | 1.5700 - 4.4810 |
| Volume | |
| Avg. Volume | 45,464 |
| Market Cap | 35.399M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | 1.40 |
| EPS (TTM) | 1.7200 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GlobeNewswireVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.